The results of the trial demonstrated that levomilnacipran showed improvement in all dose groups, in comparison to placebo.
Levomilnacipran, a sustained-release formulation, once-daily treatment was well tolerated in the study.
Forest Research Institute R&D president Marco Taglietti said these positive Phase III results are encouraging and support the continued research of levomilnacipran in adult patients with major depressive disorder..